BILA 2185 BS

Drug Profile

BILA 2185 BS

Latest Information Update: 30 Nov 2000

Price : $50

At a glance

  • Originator Boehringer Ingelheim (Canada)
  • Class Antivirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 Nov 2000 Discontinued-Preclinical for HIV infections treatment in Canada (PO)
  • 10 Aug 1999 No-Development-Reported for HIV infections treatment in Canada (PO)
  • 09 Sep 1997 Preclinical development for HIV infections treatment in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top